Blue Jet Healthcare Limited
NSE: BLUEJETPharmaceuticals
Share price
₹514.60
-0.76% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 6 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
55
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹9,006 Cr
P/E ratio
38.5
P/B ratio
6.6
ROCE
26.1%
ROE
19.9%
Dividend yield
0.2%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales fell 27.5% over the past year. Meanwhile what it keeps of every 100 rupees of sales slipped from 31.7% to 30.4% over the last three years.
Whether it grew faster than its sector
It grew 14.6% a year against a sector median of 13.1% — 1.6 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 2.6 times its growth rate, on earnings growth of 15%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Blue Jet Healthcare Limited — this one | 15%/yr | 38.8× | ₹2.6 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 19 of 130 on returns, 44 of 127 on growth, 20 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 26.1% on capital, ahead of 85% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹909 crore of cash from the business, spent ₹552 crore on plant and equipment, and returned ₹112 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 7 years, about 87 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 103 days for its cash to waiting 136 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue rose to INR293 crores as PI/API supplies restarted, while contrast media was held back by INR30-odd crores of goods in transit.
Announced 3 Aug 2026 · Standalone · Unaudited
Revenue
₹293 Cr
Net profit
₹78 Cr
Net margin
26.7%
EPS
₹4.51
Earnings call transcript · 3 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹9,006 Cr
- Prev close
- ₹514.60
- 52w High
- ₹693
- 52w Low
- ₹325
- Enterprise value
- ₹8,674 Cr
- Beta
- 1.5
- Price CAGR 1y
- -21.0%
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 15.1%
- PEG ratio
- 2.8
- P/E ratio
- 38.5
- P/B ratio
- 6.6
- EV / EBITDA
- 32.0
- Industry P/E
- 37.6
- ROCE
- 26.1%
- ROCE 5y average
- 36.8%
- ROE
- 19.9%
- Debt / Equity
- 0.0
- Interest coverage
- 56.5
- Dividend yield
- 0.2%
- ROE 3y average
- 24.0%
- ROE last year
- 19.0%
Annual P&L
- Annual revenue
- ₹947 Cr
- Annual profit
- ₹248 Cr
- Operating margin
- 31.0%
- Net profit margin
- 26.2%
- EBITDA margin
- 31.0%
- Sales growth 3y
- 9.5%
- Sales growth 5y
- 13.7%
- Profit growth 3y
- 15.0%
- Profit growth 5y
- 11.0%
- EPS
- ₹14.3
- Sales growth TTM
- -28.0%
- Profit growth TTM
- -34.0%
- Dividend payout
- 8.0%
Quarter P&L
- Sales latest quarter
- ₹293 Cr
- Profit latest quarter
- ₹78 Cr
- YoY quarterly sales growth
- -17.4%
- YoY quarterly profit growth
- -14.3%
- OPM latest quarter
- 33.5%
Balance Sheet
- Book Value
- ₹77.7
- Face Value
- ₹2.0
- Total debt
- ₹44 Cr
- Total cash
- ₹149 Cr
- Borrowings
- ₹44 Cr
- Reserves / Equity
- 37.9
Cash Flow
- Operating cash flow
- ₹334 Cr
- Free cash flow
- ₹115 Cr
- FCF yield
- 1.2%
- Net cash flow
- ₹28 Cr
Shareholding
- Promoter holding
- 73.2%
- FII holding
- 0.8%
- DII holding
- 7.5%
- Public holding
- 18.6%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,804.10 | 34.2 | 4,32,305 | 0.89 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,550.00 | 85.1 | 2,53,522 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,772.00 | 81.6 | 1,82,155 | 0.80 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,159.50 | 23.8 | 1,15,661 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,050.00 | 101.7 | 1,11,181 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,340.20 | 30.3 | 1,08,271 | 0.97 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.4 | 1,03,222 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Blue Jet Health | 538.15 | 43.4 | 10,198 | 0.22 | 78.3 | -14.2 | 293.1 | -17.4 | 26.1 |
| Median | 427.80 | 34.6 | 2,219 | 0.08 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Expenses | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 | 195 |
| Material Cost | 163 | 108 | 108 | 79 | 93 | 179 | |||||||
| Change in Inventories | -10 | 75 | -51 | 14 | 9.32 | -42 | |||||||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Employee Cost | 16 | 17 | 19 | 19 | 18 | 20 | |||||||
| Other Expenses | 31 | 33 | 34 | 34 | 43 | 38 | |||||||
| Operating Profit | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 | 71 | 98 |
| OPM % | 33 | 35 | 33 | 29 | 27 | 33 | 39 | 41 | 34 | 33 | 24 | 30 | 33 |
| Other Income | 5 | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 | 13 | 23 | 15 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 1 | 1 |
| Depreciation | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 |
| Profit before tax | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 | 54 | 87 | 106 |
| Tax % | 24 | 26 | 27 | 27 | 24 | 24 | 25 | 25 | 26 | 24 | 25 | 26 | 26 |
| Net Profit | 44 | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| EPS in Rs | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
| Diluted EPS in Rs | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 947 | 886 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 653 | 614 |
| Material Cost | 540 | 388 | ||||||
| Change in Inventories | -79 | 48 | ||||||
| Purchases of Stock-in-Trade | 0 | 0 | ||||||
| Employee Cost | 61 | 74 | ||||||
| Other Expenses | 130 | 144 | ||||||
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 | 271 |
| OPM % | 40 | 41 | 36 | 30 | 32 | 37 | 31 | 31 |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 69 | 76 |
| Exceptional items (within Other Income) | 0 | 0 | ||||||
| Interest | 7 | 5 | 3 | 1 | 0 | 0.10 | 6.24 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 | 25 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 333 | 316 |
| Tax % | 25 | 26 | 25 | 26 | 26 | 25 | 25 | |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 248 | 235 |
| EPS in Rs | 24,118 | 1,429 | 10 | 9.23 | 9.44 | 18 | 14 | 14 |
| Diluted EPS in Rs | 18 | 14 | ||||||
| Dividend Payout % | 0 | 0 | 0 | 0 | 11 | 7 | 8 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 14%
- 3 years
- 10%
- TTM
- -28%
Compounded profit growth
- 10 years
- —
- 5 years
- 11%
- 3 years
- 15%
- TTM
- -34%
Stock price CAGR
- 10 years
- —
- 5 years
- —
- 3 years
- —
- 1 year
- -21%
Return on equity
- 10 years
- —
- 5 years
- 26%
- 3 years
- 24%
- Last year
- 19%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 44 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 238 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| Fixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 316 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 771 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 122 | 137 | 146 | 142 | 241 | 46 | 334 |
| Cash from Investing Activity | -45 | -61 | -76 | -147 | -264 | -35 | -276 |
| Cash from Financing Activity | -72 | -21 | -56 | -4 | -2 | -19 | -31 |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 136 |
| ROCE % | 58 | 53 | 35 | 30 | 40 | 26 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
-332inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
4,04,70,085inr
2026-03-31
News
News and filings about Blue Jet Healthcare Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- 3-Amino-1,2-Propanediol (APD)
- caustic soda lye
- iodine
- methanol
- nitric acid
- phthalimide
- purified isophthalic acid
- sulphuric acid
Sells to
- Bracco Imaging · Contrast media intermediates
- Colgate-Palmolive India · Saccharin and its salts (high-intensity sweetener)
- Esperion Therapeutics · Bempedoic acid intermediate (CDMO / pharma intermediate)
- GE Healthcare · X-ray contrast media intermediates (ABA-HCL for iodinated contrast media); largest custome…
- Guerbet · Iodinated contrast media intermediates (ABA-HCL) and new products
- Hindustan Unilever · Saccharin and its salts (high-intensity sweetener)
- Hovione Farmaciencia · Pharma intermediates / APIs (CDMO contract manufacturing)
- Olon · Pharma intermediates / APIs (CDMO contract manufacturing)
- Prinova · Saccharin / high-intensity sweetener (ingredient distribution)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE0KBH01020
Plants
- Rambilli Cluster Phase 2 (Vizag)
- Unit I - Shahad · Shahad, Maharashtra
- Unit II - Ambernath · Ambernath, Maharashtra
- Unit III - Mahad · Mahad, Maharashtra
- Unit IV - Ambernath (Morivali)
News impact
Big market events that reach Blue Jet Healthcare Limited, and how the effect spreads.
25 Sept, 12:10 IST · Market event · high impact
Small-Cap Penny Stock Blue Cloud Share Price Jumps Over 17% After US Arm Gets Contract From IBM Cloud
Blue Cloud's US arm won a Rs 147 crore IBM order, helping Blue Cloud holders (not listed) while similarly named stocks see no gain and no one is hurt.
Who it hits first
- Blue Cloud, a small software firm, said its US arm won a Rs 147 crore fixed-fee order from IBM Cloud to run AI computer systems in the US, and its penny stock jumped over 17%.
- The listed Blue Cloud shares are not in our data table, so no signal is made for the winner itself; the four similarly named firms below are different businesses.
Who may gain
- Blue Cloud shareholders, who saw the stock jump over 17% on the IBM order
- The US subsidiary team that will execute the Rs 147 crore AI work
Along the supply chain
Downstream
Downstream is IBM Cloud in the US, which receives the AI infrastructure work from Blue Cloud's US arm.
Upstream
No upstream link in the pack — server and chip vendors to Blue Cloud are not named, so no supplier call is made.
Where demand moves
Business
Real business flows to Blue Cloud's US arm — Rs 147 crore of AI infrastructure services for IBM Cloud in the US.
Capital
Trading money chased the Blue Cloud penny stock on the news, up over 17%, while the similarly named Blue Star, Blue Dart, Blue Coast and Blue Jet saw no such inflow.
How it spreads across sectors
Information Technology
Company-specific lift only — Blue Cloud gains the work while other software firms see no spillover; no govt-capex chain as this is IT services, not building work.
A pattern seen before
Cascade chain
Pattern name
Govt Capex Cascade
Patterns
- Govt Capex Cascade
Sectors queried
- Banking
- Capital Goods
- Cement
- Infrastructure
- Steel
When it plays out
Immediate
Blue Cloud stock stays volatile over 1-7 days as traders track the Rs 147 crore execution.
Medium term
Over 1-6 months, the stock rests on delivery and whether more IBM work arrives; wrong-name peers stay flat.
Short term
Over 1-4 weeks, price follows proof of work starting and talk of further IBM orders.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 11 Sep 2026 | unspecified | ₹1.2 |
|---|---|---|
| 19 Sep 2025 | unspecified | ₹1.2 |
| 17 Sep 2024 | unspecified | ₹1 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 2, delete 1, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-2618 Aug 2026
- Earnings call · Q1FY273 Aug 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2625 May 2026
- Earnings call · Q3FY2613 Feb 2026
- Annual report · 2024-252 Sep 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.